$PODD earnings report

Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency). AlphAI read Insulet's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readPODD · Third Quarter 2026 · ended September 30, 2026

Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency)

✓Strong quarter

Revenue grew 19.2%, or 19.6% in constant currency, with total Omnipod revenue up 19.7%, operating margin expanding 590 basis points, adjusted EPS rising 59.9%, and full-year constant-currency revenue guidance maintained to increased by segment.

Revenue
$842M
19.2% y/y
U.S. Omnipod
$570M
14.7% y/y
Gross margin · GAAP
75.1%
EPS · non-GAAP
$1.99
59.9% y/y
Year ending December 31, 2026 outlook
Total revenue growth: 22% - 23% GAAP; 21% - 22% constant currency

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Revenue growth in constant currency, Q317.5% - 19.5% in constant currency19.6% in constant currencyabove

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 revenueGAAP$842M–19.2%
Q3 2026 revenue growthnon-GAAP19.6% in constant currency–19.6% in constant currency
Nine months ended September 30, 2026 revenueGAAP$2.41B–25.0%
Nine months ended September 30, 2026 revenue growthnon-GAAP23.8% in constant currency–23.8% in constant currency
Q3 2026 cost of revenueGAAP$209.9M––
Q3 2026 gross profitGAAP$632.1M––
Q3 2026 gross marginGAAP75.1%––
Q3 2026 adjusted gross profitnon-GAAP$624.9M––
Q3 2026 adjusted gross marginnon-GAAP74.2%––
Q3 2026 research and development expensesGAAP$91.6M––
Q3 2026 selling, general and administrative expensesGAAP$350.7M––
Q3 2026 operating incomeGAAP$189.8M––
Q3 2026 operating marginGAAP22.5% of revenue–up 590 basis points over prior year
Q3 2026 adjusted operating incomenon-GAAP$185.2M––
Q3 2026 adjusted operating marginnon-GAAP22.0% of revenue–up 490 basis points compared to prior year
Q3 2026 interest expense, netGAAP−$12.1M––
Q3 2026 loss on extinguishment of debtGAAP−$300K––
Q3 2026 income before income taxesGAAP$177.2M––
Q3 2026 income tax expenseGAAP−$36.1M––
Q3 2026 effective tax rateGAAP20.4%––
Q3 2026 net incomeGAAP$141.1M––
Q3 2026 diluted earnings per shareGAAP$2.03––
Q3 2026 adjusted net incomenon-GAAP$138M–57.2%
Q3 2026 adjusted diluted earnings per sharenon-GAAP$1.99–59.9%
Q3 2026 adjusted EBITDAnon-GAAP$233.7M––
Q3 2026 adjusted EBITDA marginnon-GAAP27.7%––
Nine months ended September 30, 2026 gross profitGAAP$1.72B––
Nine months ended September 30, 2026 operating incomeGAAP$441.5M––
Nine months ended September 30, 2026 operating marginGAAP18.4%––
Nine months ended September 30, 2026 net incomeGAAP$327.1M––
Nine months ended September 30, 2026 diluted earnings per shareGAAP$4.69––
Nine months ended September 30, 2026 adjusted operating incomenon-GAAP$473.2M––
Nine months ended September 30, 2026 adjusted operating marginnon-GAAP19.7%––
Nine months ended September 30, 2026 adjusted net incomenon-GAAP$352.8M––
Nine months ended September 30, 2026 adjusted diluted earnings per sharenon-GAAP$5.06––
Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP$615.1M––
Nine months ended September 30, 2026 free cash flownon-GAAP$211.7M––

Segments

SegmentRevenueq/qy/y
U.S. OmnipodThe Company completed its U.S. sales force expansion and continued its Type 2 action plan through onboarding and customer-support improvements, enhanced sampling, and sales-force compensation aligned with new customer start and retention goals.$570.4M–14.7%
International OmnipodThe Company expanded Abbott’s FreeStyle Libre 3 Plus CGM integration across Belgium, Netherlands, UK, Italy, Finland, Norway, Sweden, Australia, Switzerland and Germany.$266.2M–31.7%, or 33.0% in constant currency
Total Omnipod ProductsOmnipod represented the principal contributor to total revenue growth.$836.6M–19.7%, or 20.0% in constant currency
Drug DeliveryNo specific quarterly revenue driver was disclosed.$5.5M–(22.7)%

Year ending December 31, 2026 outlook

  • RevenueTotal revenue growth: 22% - 23% GAAP; 21% - 22% constant currency
  • NoteU.S. Omnipod revenue growth: 17.5% - 18.5% GAAP; 17.5% - 18.5% constant currency
  • NoteInternational Omnipod revenue growth: 35% - 36% GAAP; 32% - 33% constant currency
  • NoteTotal Omnipod revenue growth: 22.5% - 23.5% GAAP; 21.5% - 22.5% constant currency
  • NoteDrug Delivery revenue growth: ~(40.0%) GAAP; ~(40%) constant currency
  • NoteAdjusted Operating Margin: ~150 bps YoY expansion
  • NoteAdjusted EPS Growth: >30%

Capital returns

  • Received approval from the Board of Directors for a $1 billion share repurchase program.
  • The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash.

What drove it

  • Total revenue increased 19.2%, or 19.6% in constant currency, and was slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates.
  • Total Omnipod revenue rose 19.7%, or 20.0% in constant currency, led by 31.7% International Omnipod growth and 14.7% U.S. Omnipod growth.
  • The Company completed the full U.S. market release of Omnipod Discover, with adoption by more than 35,000 users and 5,000 healthcare professionals across available markets.
  • The Company completed enrollment in the STRIVE2 type 1 diabetes cohort and the EVOLVE pivotal study.
  • Q3 operating margin was 22.5%, up 590 basis points over prior year, while adjusted operating margin was 22.0%, up 490 basis points compared to prior year.

Concerns

  • Drug Delivery revenue was $5.5 million and declined (22.7)%.
  • Nine-month free cash flow was $211.7 million compared with $329.5 million in 2025, while capital expenditures were $(113.9) million compared with $(56.5) million in 2025.
  • The Company cited risks including international regulatory, commercial and logistics risks, potential tariff expansion, dependence on a principal product platform, competitive products, manufacturing and supply-chain challenges, reimbursement risk, product safety issues, and cybersecurity risk.
  • The Company reported voluntary medical device corrections issued in March and May 2026, reflected in adjustments to estimated warranty and related costs.

What to watch

  • Execution of the Type 2 action plan, including new customer starts, retention, onboarding, sampling, and the completed U.S. sales-force expansion.
  • Delivery against FY 2026 constant-currency guidance of 17.5% - 18.5% for U.S. Omnipod, 32% - 33% for International Omnipod, and 21% - 22% for total revenue.
  • Whether adjusted operating margin achieves the guided ~150 bps YoY expansion.
  • Execution of approximately $400 million of expected fourth-quarter 2026 share repurchases under the $1 billion authorization.
  • Progress of the STRIVE2 and EVOLVE clinical trials supporting Omnipod 6 and fully closed-loop automated insulin delivery for adults with type 2 diabetes.

Balance sheet and cash flow

  • Cash and cash equivalents were $584.4 million as of September 30, 2026, compared with $716.1 million as of December 31, 2025.
  • Current portion of long-term debt was $19.1 million as of September 30, 2026, compared with $18.4 million as of December 31, 2025.
  • Long-term debt, net was $943.0 million as of September 30, 2026, compared with $930.8 million as of December 31, 2025.
  • Net cash provided by operating activities for the nine months ended September 30, 2026 was $325.7 million, compared with $386.0 million in 2025.
  • Capital expenditures for the nine months ended September 30, 2026 were $(113.9) million, compared with $(56.5) million in 2025.
  • Free cash flow for the nine months ended September 30, 2026 was $211.7 million, compared with $329.5 million in 2025.
  • Accounts receivable, net was $689.0 million as of September 30, 2026, compared with $516.9 million as of December 31, 2025.
  • Inventories were $552.1 million as of September 30, 2026, compared with $452.6 million as of December 31, 2025.

Analysis

Insulet reported a strong third quarter, with revenue of $842.0 million, up 19.2%, or 19.6% in constant currency. The result was slightly above the high end of the Company’s 17.5% - 19.5% constant-currency guidance range. Omnipod remained the revenue engine, contributing $836.6 million and growing 19.7%, or 20.0% in constant currency. International Omnipod revenue of $266.2 million grew 31.7%, or 33.0% in constant currency, materially faster than U.S. Omnipod revenue growth of 14.7% on $570.4 million of revenue. Drug Delivery revenue was $5.5 million and declined (22.7)%.

Profitability expanded sharply. GAAP gross margin was 75.1%, while GAAP operating income reached $189.8 million and operating margin was 22.5%, up 590 basis points over prior year. Adjusted operating income was $185.2 million and adjusted operating margin was 22.0%, up 490 basis points compared to prior year. GAAP net income was $141.1 million, or $2.03 per diluted share, versus $87.6 million, or $1.24 per diluted share. Adjusted net income was $138.0 million, up 57.2%, and adjusted diluted EPS was $1.99, up 59.9%.

The nine-month figures show continued revenue growth and earnings expansion, although cash conversion was lower than the prior-year period. Revenue was $2,405.4 million, up 25.0%, and adjusted EBITDA was $615.1 million, compared with $451.5 million. Net cash provided by operating activities was $325.7 million, compared with $386.0 million, while capital expenditures increased to $(113.9) million from $(56.5) million. As a result, free cash flow was $211.7 million versus $329.5 million. Cash and cash equivalents were $584.4 million, and long-term debt, net was $943.0 million, as of September 30, 2026.

Capital allocation shifted toward repurchases. The Board authorized a $1 billion share repurchase program, and the Company expects to allocate approximately $400 million toward fourth-quarter 2026 repurchases using existing cash. This follows a quarter in which the Company emphasized commercial execution in Type 2 diabetes, completed U.S. sales-force expansion, expanded Omnipod Discover, and broadened international CGM integration.

The full-year outlook calls for 21% - 22% constant-currency total revenue growth, with U.S. Omnipod growth of 17.5% - 18.5%, International Omnipod growth of 32% - 33%, and total Omnipod growth of 21.5% - 22.5%. Total revenue growth guidance is 22% - 23% on a GAAP basis. Management also expects approximately 150 basis points of adjusted operating-margin expansion and adjusted EPS growth of more than 30%. The guide preserves strong International Omnipod expectations and targets further profitability expansion while forecasting Drug Delivery revenue growth of approximately (40%).

Management, verbatim

Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion

Ashley McEvoy, President and CEO

We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation.

Ashley McEvoy, President and CEO

The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.

Ashley McEvoy, President and CEO

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported Q3 metrics
  • Q3 operating cash flow
  • Q3 capital expenditures
  • Q3 free cash flow
  • Dividend declaration or dividend payment information
  • Q3 GAAP gross-margin prior-year figure
  • Q3 adjusted gross-profit and adjusted gross-margin prior-year figures

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readPODD · Second Quarter 2026 · ended June 30, 2026

Second Quarter Revenue of $802 million, Increase of 23.5% (22.7% in Constant Currency)

✓Solid quarter

Revenue of $801.7 million grew 23.5%, or 22.7% in constant currency, exceeding the high end of the Company’s 20% - 22% constant-currency guidance range. Omnipod growth was broad based and adjusted operating margin expanded, although GAAP operating margin was down 250 basis points over prior year and FY 2026 total revenue growth guidance was reduced to 20% - 22% from 21% - 23%.

Revenue
$802M
23.5% y/y
U.S. Omnipod
$544M
20.1% y/y
EPS · non-GAAP
$1.66
41.5% y/y
Q3 2026 and FY 2026 outlook
Q3 2026 total revenue: 17.5% - 19.5% in constant currency; FY 2026 total revenue: 20% - 22% in constant currency

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Q2 2026 total revenue growth in constant currency20% - 22%22.7%above

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$801.7M–23.5%
Revenue growth in constant currencynon-GAAP22.7%––
Total Omnipod revenueGAAP$795.9M–24.6%
Total Omnipod revenue growth in constant currencynon-GAAP23.8%––
Drug Delivery revenueGAAP$5.8M––
Operating incomeGAAP$129.7M––
Operating income as a percentage of revenueGAAP16.2% of revenue–down 250 basis points over prior year
Adjusted operating incomenon-GAAP$154.5M––
Adjusted operating income as a percentage of revenuenon-GAAP19.3% of revenue–up over 140 basis points compared to prior year
Net incomeGAAP$95M––
Diluted earnings per shareGAAP$1.37 per diluted share––
Adjusted net incomenon-GAAP$115M–37.4%
Adjusted diluted earnings per sharenon-GAAP$1.66 per diluted share–41.5%

Segments

SegmentRevenueq/qy/y
U.S. OmnipodU.S. Omnipod revenue increased 20.1%.$544.1M–20.1%
International OmnipodThe Company launched Omnipod 5 and Omnipod Discover in Spain, the 26th country where Insulet sells Omnipod and the 20th country where Omnipod 5 is available.$251.8M–35.5%, or 32.9% in constant currency
Drug DeliveryNo revenue-growth driver was reported for Drug Delivery.$5.8M––

Q3 2026 and FY 2026 outlook

  • RevenueQ3 2026 total revenue: 17.5% - 19.5% in constant currency; FY 2026 total revenue: 20% - 22% in constant currency
  • NoteQ3 2026 U.S. Omnipod revenue growth: 14% - 16% in constant currency
  • NoteQ3 2026 International Omnipod revenue growth: 28% - 30% in constant currency
  • NoteQ3 2026 Total Omnipod revenue growth: 18% - 20% in constant currency
  • NoteQ3 2026 Drug Delivery revenue growth: ~(20%) in constant currency
  • NoteFY 2026 U.S. Omnipod revenue growth: 17% - 19% in constant currency
  • NoteFY 2026 International Omnipod revenue growth: 30% - 32% in constant currency
  • NoteFY 2026 Total Omnipod revenue growth: 21% - 23% in constant currency
  • NoteFY 2026 Drug Delivery revenue growth: ~(40%) in constant currency
  • NoteFY 2026 Adjusted Operating Margin: ~100 bps YoY expansion
  • NoteFY 2026 Adjusted EPS Growth: >30%

What drove it

  • Total Omnipod revenue was $795.9 million and rose 24.6%, or 23.8% in constant currency.
  • U.S. Omnipod revenue was $544.1 million and increased 20.1%.
  • International Omnipod revenue was $251.8 million and increased 35.5%, or 32.9% in constant currency.
  • The Company expanded the Omnipod 5 ecosystem with a next-generation algorithm designed to improve time in range and increase time spent in Automated Mode, along with expanded compatibility with Abbott’s FreeStyle Libre 3 Plus.
  • The Company presented STRIVE results supporting Omnipod 6 and EVOLUTION feasibility-study data for fully closed-loop technology for people with type 2 diabetes.

Concerns

  • GAAP operating income as a percentage of revenue was 16.2% of revenue, down 250 basis points over prior year.
  • FY 2026 total revenue growth guidance was 20% - 22% in constant currency, compared with prior guidance of 21% - 23%.
  • FY 2026 U.S. Omnipod revenue growth guidance was 17% - 19% in constant currency, compared with prior guidance of 20% - 22%.
  • FY 2026 Total Omnipod revenue growth guidance was 21% - 23% in constant currency, compared with prior guidance of 22% - 24%.
  • Management said it was updating its outlook to reflect what it is learning as it scales in type 2.

What to watch

  • Q3 2026 total revenue growth guidance of 17.5% - 19.5% in constant currency.
  • Q3 2026 U.S. Omnipod revenue growth guidance of 14% - 16% in constant currency.
  • Q3 2026 International Omnipod revenue growth guidance of 28% - 30% in constant currency.
  • FY 2026 adjusted operating margin guidance of ~100 bps YoY expansion.
  • FY 2026 adjusted EPS growth guidance of >30%.
  • Execution as the Company scales in type 2 and converts those insights into action.

Balance sheet and cash flow

  • Positive free cash flow was reported, but no amount was provided.

Analysis

Insulet reported second-quarter revenue of $801.7 million, up 23.5%, or 22.7% in constant currency. The constant-currency result exceeded the high end of the Company’s 20% - 22% guidance range. Total Omnipod revenue was $795.9 million, rising 24.6%, or 23.8% in constant currency, while Drug Delivery revenue was $5.8 million.

Growth was broad based across Omnipod geographies. U.S. Omnipod revenue was $544.1 million and increased 20.1%. International Omnipod revenue was $251.8 million, up 35.5%, or 32.9% in constant currency. The Company also launched Omnipod 5 and Omnipod Discover in Spain and expanded Omnipod 5 through a next-generation algorithm and compatibility with Abbott’s FreeStyle Libre 3 Plus.

Profitability showed a divergence between reported and adjusted measures. GAAP operating income was $129.7 million, or 16.2% of revenue, with the margin down 250 basis points over prior year. Adjusted operating income was $154.5 million, or 19.3% of revenue, with margin up over 140 basis points compared to prior year. GAAP net income was $95.0 million, or $1.37 per diluted share, versus $22.5 million, or $0.32 per diluted share, in the prior year. Adjusted net income was $115.0 million, or $1.66 per diluted share, increasing 37.4% and 41.5%, respectively, compared with $83.7 million and $1.17 per diluted share.

The outlook reset is concentrated in U.S. and total growth expectations. FY 2026 total revenue growth guidance is 20% - 22% in constant currency versus prior guidance of 21% - 23%, and U.S. Omnipod guidance is 17% - 19% versus 20% - 22%. International Omnipod guidance increased to 30% - 32% from 26% - 28%. The Company maintained guidance for ~100 bps YoY adjusted operating-margin expansion and raised adjusted EPS growth guidance to >30% from >25%.

Management, verbatim

We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow, reflecting the strength of the Omnipod platform. While we are updating our outlook to reflect what we're learning as we scale in type 2, our conviction in the long-term opportunity remains unchanged.

Ashley McEvoy, President and CEO

We remain focused on converting those insights into action, further strengthening execution and positioning the business for durable, profitable growth.

Ashley McEvoy, President and CEO

Not in the filing

stated, not guessed
  • GAAP gross profit and gross margin
  • Adjusted gross profit and adjusted gross margin
  • Operating expenses
  • Income tax expense or benefit and tax rate
  • Operating cash flow amount
  • Free cash flow amount
  • Capital expenditures
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Adjusted EBITDA
  • Prior-quarter comparisons for reported metrics
  • Prior-year revenue amount
  • Prior-year operating income amount
  • Prior-year adjusted operating income amount
  • Revenue-dollar guidance
  • Q3 2026 adjusted operating margin guidance
  • Q3 2026 adjusted EPS growth guidance
  • FY 2026 gross-margin, operating-expense, and tax-rate guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about PODD earnings dates

When is Insulet's next earnings date?
AlphAI has no date for PODD yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.